Dr Kristen Radford
Position:
- Senior Research Fellow, Immunotherapy Program, Mater Medical Research Institute
- Team Leader, DC Cancer Team
- Honorary Advisor, Faculty of Medicine, Southern Clinical Division, University of Queensland
Websites:
Biography:
Immunotherapy is a promising non-toxic strategy for the treatment of prostate cancer and other diseases. It works by teaching the patient's own immune system to recognize and destroy the cancer. Specialized blood cells called dendritic cells (DC) are essential to this process but they are poorly understood in humans. We have pioneered methods to isolate and characterise rare human DC subsets in healthy donors and prostate cancer patients and have completed a phase I DC clinical trial in prostate cancer patients at MMRI. My team is focussed on investigating the roles of specific DC subsets in the induction of anti-cancer immune responses. This information is essential for the design of new immunotherapeutic strategies for prostate cancer. We are also interested in identifying new immunogneic molecules expressed in prostate cancer but not in healthy tissue that can be used as vaccine targets.
cancer immunology, immunotherapy, systemic therapies, vaccines, dendritic cells.
